Dana T. Aftab,Sriram Naganathan,Wei Xu,Steven Lacy
申请号：
US16776139
公开号：
US20200163954A1
申请日:
2020.01.29
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′；-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
